儿童1型糖尿病高血压与高低密度脂蛋白的管理现状调查
该研究通过电子调查评估儿科糖尿病提供者对1型糖尿病青少年高血压和高脂血症的管理模式。结果显示,大多数受访者初始推荐生活方式和非药物干预,但仅少数认为这些措施有效;许多提供者对高血压转诊专科,而约五分之一从不启动降压药物。结论认为需要努力使临床实践与指南一致。
要点
- 大多数提供者初始推荐生活方式和非药物干预,但仅6%-17%认为有效。
- 57%的提供者对高血压转诊专科,仅8%对高脂血症转诊专科。
- 21%的提供者从不启动降压药物,8%从不启动降脂药物。
核心结论
- 儿科糖尿病提供者通常推迟处方降压和降脂药物,直到非药物干预无效。
- 大多数提供者认为药物有效,而非生活方式干预有效。
- 需要努力使临床实践与临床指南一致。
研究设计与样本
- 电子调查,包括临床场景,发送给儿科提供者(美国糖尿病协会青年糖尿病兴趣小组、儿科内分泌学会或T1D Exchange成员)。
- 受访者N=207,86%为医学博士,68%为女性,均为1型糖尿病青少年的执业临床医生。
主要发现
- 作为初始推荐,绝大多数受访者(83%-99%)支持生活方式和非医学推荐(如改善血糖控制)用于高血压和高脂血症。
- 少数(6%-17%)报告这些推荐有效。
- 许多受访者(57%)报告将高血压转诊至其他专科,而少数(8%)报告将高脂血症管理转诊至其他专科。
- 约五分之一(21%)的受访者从不启动降压药物,而仅8%从不启动降脂药物。
- 在处方者中,大多数受访者仅在持续升高且生活方式或非医学干预无效或有额外心血管风险因素时才开始降压或降脂药物。
临床怎么用
- 临床实践中应关注提供者对非药物干预有效性的低感知,并促进指南对齐。
- 考虑转诊专科的差异:高血压转诊较多,高脂血症转诊较少。
- 注意部分提供者从不启动降压或降脂药物,需加强处方实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management. STUDY DESIGN: An electronic survey, including clinical scenarios, fielded to pediatric providers (members of the American Diabetes Association Diabetes in Youth Interest Group, Pediatric Endocrine Society, or T1D Exchange). RESULTS: Respondents (N = 207, 86% MDs, 68% female) were practicing clinicians for youth with type 1 diabetes. As an initial recommendation, the overwhelming majority of respondents (83%-99%) endorsed lifestyle and nonmedical recommendations (eg, improve glycemic control) for hypertension and hyperlipidemia. Yet, few (6%-17%) reported these recommendations as effective. Many respondents (57%) reported referring to another specialist for hypertension, whereas few (8%) reported referring to another specialist for hyperlipidemia management. Approximately one-fifth (21%) of respondents never initiate antihypertensive medications, whereas only 8% never initiate lipid-lowering medication. Among prescribers, the majority of respondents only started antihypertensive or lipid-lowering medications after persistent elevations and in the setting of either ineffective lifestyle or nonmedical interventions or additional cardiovascular risk factors. More than two-thirds of respondents endorsed medications as often effective for hypertension and hyperlipidemia (68% and 69%, respectively). CONCLUSIONS: Pediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed.
引用
- Katz ML, Guo Z, Laffel LM, et al. Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes. J Pediatr. 2018. PMID: 29395184. doi:10.1016/j.jpeds.2017.11.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。